

Albert C Koong

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/2310120/publications.pdf](https://exaly.com/author-pdf/2310120/publications.pdf)

Version: 2024-02-01

211
papers

14,120
citations

15732

62
h-index

20209

111
g-index

241
all docs

241
docs citations

241
times ranked

15310
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing Outpatient Radiation Oncology Consult Workflow by Using Time-Driven Activity-Based Costing: Efficiency and Financial Impacts. <i>JCO Oncology Practice</i> , 2024, 20, 732-738.	2.8	1
2	IRE1 β determines ferroptosis sensitivity through regulation of glutathione synthesis. <i>Nature Communications</i> , 2024, 15, .	13.2	2
3	Implementation and Assessment of an Informal Virtual Elective for Medical Student Radiation Oncology Exploration During the COVID19 Pandemic: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 344-348.	1.4	1
4	Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. <i>Cancer Research</i> , 2023, 83, 441-455.	0.9	31
5	Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, 42-45.	1.7	2
6	Design and validation of a synchrotron proton beam line for FLASH radiotherapy preclinical research experiments. <i>Medical Physics</i> , 2022, 49, 497-509.	3.1	17
7	Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence. <i>Clinical Colorectal Cancer</i> , 2022, 21, 204-211.	2.4	1
8	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. <i>Cancer Immunology Research</i> , 2022, 10, 259-271.	3.3	11
9	Stress-induced tyrosine phosphorylation of RtcB modulates IRE1 activity and signaling outputs. <i>Life Science Alliance</i> , 2022, 5, e202201379.	3.0	10
10	Patient, physician, and policy factors underlying variation in use of telemedicine for radiation oncology cancer care. <i>Cancer Medicine</i> , 2022, , .	2.9	6
11	Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 9-16.	1.9	2
12	Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1901.	3.9	20
13	Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. <i>Cancer</i> , 2022, 128, 2529-2539.	4.1	9
14	Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. <i>International Journal of Particle Therapy</i> , 2022, 9, 18-27.	1.9	1
15	Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.8	6
16	Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5167-5179.	7.3	35
17	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1069-1081.	7.3	92
18	Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100621.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.	3.8	25
20	Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 147-151.	1.9	0
21	A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 135-142.	0.9	8
22	Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. <i>Advances in Radiation Oncology</i> , 2021, 6, 100763.	1.3	21
23	Definitive or Palliative Radiotherapy for Unresectable Pancreatic Cancer. , 2021, , 1255-1266.		0
24	Radiotherapy clinical trial enrollment during the COVID-19 pandemic. <i>Acta OncolÃ³gica</i> , 2021, 60, 312-315.	1.9	8
25	Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2412-2422.	1.4	4
26	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.4	0
27	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777.	5.3	17
28	Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1270.	2.6	3
29	Automated hepatobiliary toxicity prediction after liver stereotactic body radiation therapy with deep learning-based portal vein segmentation. <i>Neurocomputing</i> , 2020, 392, 181-188.	6.2	6
30	Predicting Survival for Patients With Metastatic Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 52-60.	0.9	18
31	IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 369-376.	1.3	6
32	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 567-572.	1.3	12
33	Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. <i>Radiotherapy and Oncology</i> , 2020, 152, 63-69.	0.6	20
34	Telemedicine for Radiation Oncology in a Post-COVID World. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 407-410.	0.9	22
35	Understanding the Intersection of Working from Home and Burnout to Optimize Post-COVID19 Work Arrangements in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 370-373.	0.9	41
36	Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice. <i>Scientific Reports</i> , 2020, 10, 21600.	3.5	143

#	ARTICLE	IF	CITATIONS
37	Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 252-257.	0.6	20
38	Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk. <i>Advances in Radiation Oncology</i> , 2020, 5, 743-745.	1.3	12
39	Deep learning for identification of critical regions associated with toxicities after liver stereotactic body radiation therapy. <i>Medical Physics</i> , 2020, 47, 3721-3731.	3.1	25
40	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1586-1595.	2.0	10
41	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1569-1579.	5.3	184
42	The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. <i>Practical Radiation Oncology</i> , 2020, 10, 274-281.	2.1	8
43	Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image Guided Stereotactic Body Radiation Therapy in the Abdomen. <i>Practical Radiation Oncology</i> , 2020, 10, 434-442.	2.1	17
44	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , 2020, 181, 832-847.e18.	28.1	86
45	Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1085-1087.	1.2	16
46	Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations. <i>Clinical Cancer Research</i> , 2020, 26, 2972-2985.	7.3	9
47	A multi-scale integrated analysis identifies KRT8 as a pan-cancer early biomarker. , 2020, , .		8
48	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. <i>Genetics in Medicine</i> , 2019, 21, 213-223.	2.5	166
49	Markerless Pancreatic Tumor Target Localization Enabled By Deep Learning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 432-439.	0.9	52
50	Enhancing clinical trial enrollment at MD Anderson Cancer Center satellite community campuses. <i>Acta Oncologica</i> , 2019, 58, 1135-1137.	1.9	2
51	Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration-based image guidance. <i>Radiation Oncology</i> , 2019, 14, 154.	2.8	8
52	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2019, 9, 322-332.	2.1	130
53	Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 59-65.	1.9	17
54	EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 659-670.e18.	1.0	33

#	ARTICLE	IF	CITATIONS
55	The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 133, 9-15.	0.6	54
56	Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. <i>VideoGIE</i> , 2019, 4, 223-225.	0.7	22
57	Neural Networks for Deep Radiotherapy Dose Analysis and Prediction of Liver SBRT Outcomes. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 1821-1833.	6.9	27
58	Effect of setup and inter-fraction anatomical changes on the accumulated dose in CT-guided breath-hold intensity modulated proton therapy of liver malignancies. <i>Radiotherapy and Oncology</i> , 2019, 134, 101-109.	0.6	12
59	Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. <i>Pancreas</i> , 2019, 48, 622-628.	1.1	12
60	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5553-5567.	6.7	106
61	Present developments in reaching an international consensus for a model-based approach to particle beam therapy. <i>Journal of Radiation Research</i> , 2018, 59, i72-i76.	1.8	8
62	Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1-2.	6.6	34
63	¹⁸ F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1183-1192.	0.9	22
64	A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1 α -XBP1 Activation. <i>Molecular Cancer Research</i> , 2018, 16, 745-753.	3.5	14
65	Strategies for prediction and mitigation of radiation-induced liver toxicity. <i>Journal of Radiation Research</i> , 2018, 59, i40-i49.	1.8	38
66	Resectable and Borderline Resectable Pancreatic Cancer. <i>Practical Guides in Radiation Oncology</i> , 2018, , 199-229.	0.0	0
67	High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 584-590.	0.6	60
68	Management of Borderline Resectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1155-1174.	0.9	48
69	Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 242-247.	1.3	58
70	Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2018, 4, e173420.	7.4	164
71	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 486-489.	0.9	2
72	Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1044-1053.	1.4	6

#	ARTICLE	IF	CITATIONS
73	Dose escalation for locally advanced pancreatic cancer: How high can we go?. <i>Advances in Radiation Oncology</i> , 2018, 3, 693-700.	1.3	32
74	Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. <i>Scientific Reports</i> , 2018, 8, 14008.	3.5	27
75	Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10756-10761.	7.6	133
76	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892.	2.9	25
77	The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer. <i>Advances in Radiation Oncology</i> , 2018, 3, 297-304.	1.3	13
78	Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity. <i>Advances in Radiation Oncology</i> , 2018, 3, 621-629.	1.3	39
79	The Prognostic Significance of Pretreatment Hematologic Parameters in Patients Undergoing Resection for Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 405-412.	1.3	47
80	Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. <i>Practical Radiation Oncology</i> , 2017, 7, 173-182.	2.1	43
81	Hypoxia-Induced Endoplasmic Reticulum Stress. , 2017, , 225-247.		0
82	The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 177-185.	0.9	24
83	Chemical Space Mimicry for Drug Discovery. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 875-882.	5.7	70
84	Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. <i>Practical Radiation Oncology</i> , 2017, 7, 120-125.	2.1	6
85	Does radiotherapy still have a role in unresected biliary tract cancer?. <i>Cancer Medicine</i> , 2017, 6, 129-141.	2.9	34
86	ACR Appropriateness Criteria® Resectable Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 109-117.	1.3	7
87	Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. <i>Radiology</i> , 2017, 283, 460-468.	8.5	37
88	Perfusion CT measurements predict tumor response in rectal carcinoma. <i>Abdominal Radiology</i> , 2017, 42, 1132-1140.	2.2	11
89	Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. <i>British Journal of Cancer</i> , 2017, 117, 1874-1882.	6.6	75
90	A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. <i>Cancer Cell</i> , 2017, 32, 460-473.e6.	16.9	148

#	ARTICLE	IF	CITATIONS
91	Radiation Therapy for Hepatocellular Carcinoma: Clinical Data. , 2017, , 179-198.		0
92	BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. Cancer Discovery, 2017, 7, 1184-1199.	14.3	58
93	Radiation Therapy for Colorectal Liver Metastases. Current Colorectal Cancer Reports, 2017, 13, 240-249.	0.5	1
94	Central liver toxicity after SBRT: An expanded analysis and predictive nomogram. Radiotherapy and Oncology, 2017, 122, 130-136.	0.6	76
95	Inhibition of IRE1 results in decreased scar formation. Wound Repair and Regeneration, 2017, 25, 964-971.	3.2	8
96	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. JCO Precision Oncology, 2017, 2017, 1-9.	3.2	7
97	Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. Journal of Oncology Practice, 2017, 13, e992-e1001.	3.1	8
98	Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Pancreas, 2016, 45, 64-70.	1.1	45
99	Reprogramming the immunological microenvironment through radiation and targeting Axl. Nature Communications, 2016, 7, 13898.	13.2	155
100	Quantitative Analysis of 18F-Fluorodeoxyglucose Positron Emission Tomography Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 102-109.	0.9	46
101	Identification of Doxorubicin as an Inhibitor of the IRE1-XBP1 Axis of the Unfolded Protein Response. Scientific Reports, 2016, 6, 33353.	3.5	28
102	A Multimodal Data Analysis Approach for Targeted Drug Discovery Involving Topological Data Analysis (TDA). Advances in Experimental Medicine and Biology, 2016, 899, 253-268.	9.0	6
103	Acridine Derivatives as Inhibitors of the IRE1-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 2055-2065.	3.7	25
104	Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. Journal of Clinical Investigation, 2016, 127, 183-198.	6.7	90
105	A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS ONE, 2016, 11, e0147995.	2.4	13
106	ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 520-525.	1.3	1
107	Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 564-569.	1.3	28
108	Targeting the IRE1-XBP1 branch of the unfolded protein response in human diseases. Seminars in Cancer Biology, 2015, 33, 48-56.	9.8	144

#	ARTICLE	IF	CITATIONS
109	Emerging Treatment Paradigms in Radiation Oncology. <i>Clinical Cancer Research</i> , 2015, 21, 3393-3401.	7.3	34
110	Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. <i>Scientific Reports</i> , 2015, 5, 10291.	3.5	27
111	Comparison of film measurements and Monte Carlo simulations of dose delivered with very high-energy electron beams in a polystyrene phantom. <i>Medical Physics</i> , 2015, 42, 1606-1613.	3.1	42
112	Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 568-576.	0.9	78
113	Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 741-759.	1.9	9
114	Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. <i>Cancer</i> , 2015, 121, 1128-1137.	4.1	456
115	Predictors of Toxicity Associated With Stereotactic Body Radiation Therapy to the Central Hepatobiliary Tract. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 986-994.	0.9	66
116	Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 341-345.	2.2	38
117	CyberKnife. , 2015, , 147-161.		1
118	Plant stilbenes induce endoplasmic reticulum stress and their anti-cancer activity can be enhanced by inhibitors of autophagy. <i>Experimental Cell Research</i> , 2015, 339, 147-153.	2.6	25
119	Serum Transforming Growth Factor- β 1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1023-1031.	0.9	3
120	Multiplex proximity ligation assay to identify a biomarker panel for prognosis in unresectable pancreatic cancer patients treated with stereotactic body radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, , .	0.9	0
121	Stereotactic body radiation therapy and central liver toxicity: A case report. <i>Practical Radiation Oncology</i> , 2015, 5, 282-285.	2.1	11
122	Future of Stereotactic Irradiation "Dose Composition Radiotherapy (DCRT). , 2015, , 239-250.		0
123	Anal Canal Cancer. <i>Medical Radiology</i> , 2014, , 315-325.	0.0	0
124	Irf1 Has Distinct Catalytic Mechanisms for XBP1/HAC1 Splicing and RIDD. <i>Cell Reports</i> , 2014, 9, 850-858.	6.4	151
125	Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2014, 43, 777-783.	1.1	1
126	Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 539-546.	0.9	71

#	ARTICLE	IF	CITATIONS
127	Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. <i>Practical Radiation Oncology</i> , 2014, 4, 198-206.	2.1	31
128	Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer. <i>Seminars in Radiation Oncology</i> , 2014, 24, 140-147.	2.4	50
129	Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 918-925.	0.9	100
130	High Serum Levels of Vascular Endothelial Growth Factor-A and Transforming Growth Factor- β 1 Before Neoadjuvant Chemoradiotherapy Predict Poor Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Combined Modality Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 2361-2368.	2.0	21
131	Galactin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. <i>Clinical Cancer Research</i> , 2014, 20, 5558-5569.	7.3	64
132	False positive ^{18}F -fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. <i>Practical Radiation Oncology</i> , 2014, 4, 368-371.	2.1	2
133	Stereotactic Body Radiation Therapy: A New Standard Option for Pancreatic Cancer?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1489-1493.	5.4	12
134	Neurotrophic factor GDNF promotes survival of salivary stem cells. <i>Journal of Clinical Investigation</i> , 2014, 124, 3364-3377.	6.7	97
135	Impact of Chemotherapy on Normal Tissue Complication Probability Models of Acute Hematologic Toxicity in Patients Receiving Pelvic Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 983-991.	0.9	49
136	The role of adjuvant chemoradiation in the treatment of pancreatic cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 391-400.	0.6	0
137	Dosimetric Analysis of Organs at Risk During Expiratory Gating in Stereotactic Body Radiation Therapy for Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1090-1095.	0.9	52
138	Safety of ^{90}Y Radioembolization in Patients Who Have Undergone Previous External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 323-329.	0.9	38
139	Clinical Implementation of Intrafraction Cone Beam Computed Tomography Imaging During Lung Tumor Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 917-923.	0.9	32
140	Biomarker Studies on Radiotherapy to Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 64-68.	1.9	10
141	Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer: A SEER-Medicare Analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 3999-4007.	2.0	22
142	Metabolic Tumor Volume Predicts Disease Progression and Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. <i>Journal of Nuclear Medicine</i> , 2013, 54, 27-32.	6.0	52
143	Identification and Characterization of a Potent Activator of p53-Independent Cellular Senescence via a Small-Molecule Screen for Modifiers of the Integrated Stress Response. <i>Molecular Pharmacology</i> , 2013, 83, 594-604.	2.4	12
144	Positron Emission Tomography for Predicting Pathologic Response After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 334-339.	1.3	24

#	ARTICLE	IF	CITATIONS
145	Antiangiogenic and Radiation Therapy. <i>Investigative Radiology</i> , 2012, 47, 25-32.	6.5	40
146	BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon. <i>American Journal of Surgical Pathology</i> , 2012, 36, 744-752.	4.0	161
147	Orthovoltage Intraoperative Radiotherapy for Locally Advanced and Recurrent Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 695-702.	1.5	12
148	Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e351-e358.	0.9	108
149	Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e595-e601.	0.9	35
150	Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response and Survival in Patients With Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 471-477.	0.9	54
151	Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Patients Treated With Intensity-Modulated Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 700-706.	0.9	85
152	Modern Radiation Therapy Techniques for Pancreatic Cancer. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 223-235.	2.1	9
153	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. <i>Modern Pathology</i> , 2012, 25, 1128-1139.	5.8	260
154	Combined Modality Therapy for Rectal Cancer: The Relative Value of Posttreatment Versus Pretreatment CEA as a Prognostic Marker for Disease Recurrence. <i>Annals of Surgical Oncology</i> , 2012, 19, 2471-2476.	2.0	23
155	ACR Appropriateness Criteria for Resectable Rectal Cancer. <i>Radiation Oncology</i> , 2012, 7, 161.	2.8	21
156	Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 1119-1129.	4.1	57
157	Stereotactic ablative radiotherapy: what's in a name?. <i>Practical Radiation Oncology</i> , 2011, 1, 38-39.	2.1	54
158	Rectal and bladder deformation and displacement during preoperative radiotherapy for rectal cancer: Are current margin guidelines adequate for conformal therapy?. <i>Practical Radiation Oncology</i> , 2011, 1, 85-94.	2.1	20
159	Unfolded Protein Response Regulation in Keloid Cells. <i>Journal of Surgical Research</i> , 2011, 167, 151-157.	1.7	14
160	Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. <i>Blood</i> , 2011, 117, 1311-1314.	1.4	436
161	Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. <i>Cancer</i> , 2011, 117, 3342-3351.	4.1	132
162	Stereotactic body radiotherapy for colorectal liver metastases. <i>Cancer</i> , 2011, 117, 4060-4069.	4.1	270

#	ARTICLE	IF	CITATIONS
163	Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 181-188.	0.9	236
164	Tumor Galectin-1 Mediates Tumor Growth and Metastasis through Regulation of T-Cell Apoptosis. <i>Cancer Research</i> , 2011, 71, 4423-4431.	0.9	112
165	A Novel Aldehyde Dehydrogenase-3 Activator Leads to Adult Salivary Stem Cell Enrichment <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2011, 17, 7265-7272.	7.3	60
166	Stereotactic Body Radiation Therapy for Gastrointestinal Malignancies. <i>Frontiers of Radiation Therapy and Oncology</i> , 2011, 43, 412-427.	0.0	15
167	Pathological response after chemoradiation for T3 rectal cancer. <i>Colorectal Disease</i> , 2010, 12, e24-30.	1.8	2
168	Interfractional Uncertainty in the Treatment of Pancreatic Cancer With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 603-607.	0.9	59
169	Dose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 486-493.	0.9	282
170	A Dosimetric Model of Duodenal Toxicity After Stereotactic Body Radiotherapy for Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1420-1426.	0.9	145
171	Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. <i>Cancer</i> , 2010, 116, 3943-3952.	4.1	76
172	Expression of p16 ^{INK4A} but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. <i>Cancer</i> , 2010, 116, 5179-5187.	4.1	16
173	¹⁸ Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1420-1425.	0.9	119
174	Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. <i>Radiation Oncology</i> , 2010, 5, 105.	2.8	7
175	The RGD Domain of Human Osteopontin Promotes Tumor Growth and Metastasis through Activation of Survival Pathways. <i>PLoS ONE</i> , 2010, 5, e9633.	2.4	45
176	Imaging the Unfolded Protein Response in Primary Tumors Reveals Microenvironments with Metabolic Variations that Predict Tumor Growth. <i>Cancer Research</i> , 2010, 70, 78-88.	0.9	92
177	Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. <i>Translational Oncology</i> , 2010, 3, 109-113.	3.8	289
178	Hypoxia Mediated Signaling Pathways. , 2010, , 2241-2245.		0
179	Regulation of the Unfolded Protein Response in Cancer. , 2010, , 291-310.		0
180	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. <i>Cancer</i> , 2009, 115, 665-672.	4.1	359

#	ARTICLE	IF	CITATIONS
181	Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. <i>Journal of Translational Medicine</i> , 2009, 7, 105.	4.6	51
182	A Primer on Image-guided Radiation Therapy for the Interventional Radiologist. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 859-862.	0.5	10
183	X Box-Binding Protein 1 Regulates Angiogenesis in Human Pancreatic Adenocarcinomas. <i>Translational Oncology</i> , 2009, 2, 31-IN2.	3.8	81
184	Treatment of Esophageal Cancer Based on Histology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 405-410.	1.3	43
185	Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2009, 34, 312-313.	1.5	1
186	Pancreatic Tumor Motion on a Single Planning 4D-CT Does Not Correlate With Intrafraction Tumor Motion During Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 364-368.	1.3	93
187	Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 678-686.	0.9	313
188	High-Dose Single-Fraction Radiotherapy: Exploiting a New Biology?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 324-325.	0.9	112
189	Multiplexed Proximity Ligation Assays to Profile Putative Plasma Biomarkers Relevant to Pancreatic and Ovarian Cancer. <i>Clinical Chemistry</i> , 2008, 54, 582-589.	3.5	85
190	Molecular Imaging of Hypoxia-Inducible Factor 1 α and von Hippel-Lindau Interaction in Mice. <i>Molecular Imaging</i> , 2008, 7, 7290.2008.00017.	1.5	7
191	Impact of Integrated PET/CT on Variability of Target Volume Delineation in Rectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2007, 6, 31-36.	2.0	86
192	Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer. <i>Frontiers of Radiation Therapy and Oncology</i> , 2007, 40, 386-394.	0.0	15
193	Hypoxia and the Unfolded Protein Response. <i>Methods in Enzymology</i> , 2007, 435, 275-293.	1.7	27
194	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 167-175.	0.9	111
195	Multiplexed protein detection by proximity ligation for cancer biomarker validation. <i>Nature Methods</i> , 2007, 4, 327-329.	19.6	170
196	CyberKnife Radiosurgery for Pancreatic Cancer. , 2007, , 227-239.		2
197	Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 802-809.	1.2	98
198	Targeting XBP-1 as a novel anti-cancer strategy. <i>Cancer Biology and Therapy</i> , 2006, 5, 756-759.	3.7	110

#	ARTICLE	IF	CITATIONS
199	Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers. <i>Journal of Clinical Oncology</i> , 2006, 24, 5291-5297.	5.3	61
200	Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 802-809.	1.2	196
201	Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 320-323.	0.9	313
202	Identification of Mitogen-Activated Protein Kinase Signaling Pathways That Confer Resistance to Endoplasmic Reticulum Stress in <i>Saccharomyces cerevisiae</i> . <i>Molecular Cancer Research</i> , 2005, 3, 669-677.	3.5	118
203	Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege. <i>Journal of Clinical Oncology</i> , 2005, 23, 8932-8941.	5.3	235
204	Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. <i>Oncogene</i> , 2005, 24, 6555-6563.	5.9	73
205	Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1017-1021.	0.9	423
206	Hypoxia-Mediated Signaling Pathways. , 2003, , 277-282.		0
207	Pancreatic tumors show high levels of hypoxia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 919-922.	0.9	534
208	Increased cytotoxicity of chronic hypoxic cells by molecular inhibition of GRP78 induction. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 28, 661-666.	0.9	76
209	Activators of protein kinase C selectively mediate cellular cytotoxicity to hypoxic cells and not aerobic cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 29, 259-265.	0.9	13
210	The Regulation of GRP78 and Messenger RNA Levels by Hypoxia Is Modulated by Protein Kinase C Activators and Inhibitors. <i>Radiation Research</i> , 1994, 138, S60.	1.6	39
211	Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 0, , .	5.3	0